|By Business Wire||
|June 3, 2014 04:00 AM EDT||
Cambridge Cognition (COG:LSE), the leading global provider of cognitive assessment software, has launched the first two iPad-based applications on its new Cantab Connect digital platform for use in clinical trials. Current practice still relies largely on pen and paper questionnaires with widespread potential for inaccuracies.
The Clinical Trials Information System Adverse Effects (CTIS-AE) product delivers fast, sensitive and reproducible measurement of cognitive impairment in Phase I trials. This enables early informed decisions to be made about the cognitive safety of new drugs, reducing the risk of costly late-stage failure in clinical development.
The CTIS-Abuse Liability (CTIS-AL) is a computerised patient-report system enabling rapid, accurate and paperless measurement of the abuse potential for investigational drugs in clinical trials. It enables companies to comply with FDA guidance which states that drug products with the potential for abuse should be assessed for liability. CTIS-AL provides a digital solution, with automated administration and data collection, reducing trial workloads and costs and improving data quality. This product will meet the increasing demand for abuse liability studies to assess the addictive qualities of drugs.
Cognitive safety assessment at all stages is increasingly regarded as essential to successful drug discovery and development. According to Chief Scientific Officer Dr Andrew Blackwell, Cantab Connect is a real game-changer: “sensitive, intuitive and fast, Cantab Connect provides clinical trial professionals with the first digital platform for all aspects of cognitive assessment. As well as significantly reducing errors and the labor-intensity of such work, touchscreen assessment and electronic data capture will accelerate decision making. For the first two applications we have focused on areas of particular concern: adverse effects and abuse liability. CTIS-AE is designed to enable early informed decisions in Phase I on the cognitive safety of compounds, reducing the risk of costly late stage failure. Similarly, CTIS-AL will enable compliance with regulatory guidance, which calls for all drug products with the potential for abuse to be assessed.”
Identity is in everything and customers are looking to their providers to ensure the security of their identities, transactions and data. With the increased reliance on cloud-based services, service providers must build security and trust into their offerings, adding value to customers and improving the user experience. Making identity, security and privacy easy for customers provides a unique advantage over the competition.
Aug. 27, 2016 08:45 PM EDT Reads: 2,276
Qosmos has announced new milestones in the detection of encrypted traffic and in protocol signature coverage. Qosmos latest software can accurately classify traffic encrypted with SSL/TLS (e.g., Google, Facebook, WhatsApp), P2P traffic (e.g., BitTorrent, MuTorrent, Vuze), and Skype, while preserving the privacy of communication content. These new classification techniques mean that traffic optimization, policy enforcement, and user experience are largely unaffected by encryption. In respect wit...
Aug. 27, 2016 08:45 PM EDT Reads: 1,753
Aug. 27, 2016 06:15 PM EDT Reads: 708
Aug. 27, 2016 06:00 PM EDT Reads: 3,080
Aug. 27, 2016 06:00 PM EDT Reads: 716
Aug. 27, 2016 05:15 PM EDT Reads: 1,568
Aug. 27, 2016 05:00 PM EDT Reads: 1,874
Aug. 27, 2016 04:45 PM EDT Reads: 1,621
Aug. 27, 2016 04:00 PM EDT Reads: 566
Aug. 27, 2016 03:15 PM EDT Reads: 754
Aug. 27, 2016 02:45 PM EDT Reads: 3,443
Aug. 27, 2016 12:45 PM EDT Reads: 2,340
Aug. 27, 2016 12:30 PM EDT Reads: 3,613
Aug. 27, 2016 12:00 PM EDT Reads: 520
Aug. 27, 2016 12:00 PM EDT Reads: 637